This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Measure of benefits used in the economic analysis
The summary benefit measure used in the economic evaluation was the number of life-years saved (LYS). These were obtained by combining data on the RR of ESRD obtained from the clinical trial with the life expectancy differences between individuals with and without ESRD. The long-term analysis assumed that losartan did not provide any additional clinical benefits in ESRD risk reduction beyond the trial period. An annual discount rate of 3.5% was applied. The cumulative incidence of ESRD at 4 years was also reported.
Direct costs
The analysis of the costs was carried out from the perspective of the NHS. It included the costs of losartan, haemodialysis and peritoneal dialysis. The unit costs were not presented separately from the resource quantities. The costs of non-study medications were assumed to have been similar between the two treatment groups. It was also assumed that patients who discontinued study medication incurred no additional costs. The costs associated with monitoring SCr and potassium concentration were not included because this monitoring would be performed routinely in patients with DM-2 and renal disease. The costs of treating complications associated with dialysis were also excluded from the analysis. Resource use was estimated retrospectively from the actual resource consumption observed in the RENAAL study. In the base-case, the costs of haemodialysis and peritoneal dialysis were derived from the UK Transplant website, where costs relevant to the NHS were considered. The lifetime cost of ESRD was based on an annual average cost for haemodialysis and peritoneal dialysis, weighted according to the distribution of first renal replacement therapy and the median survival time of patients undergoing diabetic renal replacement therapy (agematched to the RENAAL population). In a secondary analysis, the costs of haemodialysis and peritoneal dialysis were taken from the UK 2-Center European Dialysis and Cost-Effectiveness (EURODICE) study. The price year was 2004. Discounting was relevant and an annual rate of 3.5% was used.
Statistical analysis of costs
Statistical analyses were carried out to test the statistical significance of cost-differences between the groups by generating confidence intervals (CIs) around mean values using the bootstrapping method.
Indirect Costs
The indirect costs were not included in the analysis.
Currency
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Sensitivity analysis
Univariate sensitivity analyses were carried out to assess the robustness of the costs and benefits to variations in the cost of daily renal replacement therapy and life expectancy (increased by 50%) with losartan when on dialysis. Alternative cost estimates were based on different costing approaches (bottom-up and top-down approaches from the EURODICE study). A bootstrapping approach was also used to generate CIs around the costs and benefits.
Estimated benefits used in the economic analysis
The expected LYS were 7.82 with losartan and 7.38 with the control treatments (difference 0.44, 95% CI: 0.16 to 0.71; p=0.002).
The cumulative incidence of ESRD at 4 years was 0.193 with losartan and 0.296 with the control treatments (difference -0.102, 95% CI: -0.157 to -0.047; p<0.001).
Cost results
The medication costs per patient were 768 with losartan and 0 with the control treatments (difference 768, 95% CI: 707 to 820; p<0.001).
The ESRD-related costs per patient were 14,009 with losartan and 21,399 with the control treatments (difference -7,390, 95% CI: -11,366 to -3,414; p<0.001).
Thus, the total costs per patient were 14,777 with losartan and 21,399 with the control treatments (difference -6,622, 95% CI: -10,591 to -2,653; p=0.001).
Synthesis of costs and benefits
A synthesis of costs and benefits was not required since losartan dominated the control treatments, which were both less effective and more expensive. The costs and benefits estimated in the base-case analysis remained robust to variations in clinical and economic factors. Therefore, losartan remained the preferred treatment even under unfavourable scenarios (i.e. when the cost of renal replacement therapy was reduced by 50%).
Authors' conclusions
A losartan-based regimen in patients with Type 2 diabetes mellitus (DM-2) and nephropathy was cost-saving from the perspective of the National Health Service (NHS) in the UK because it reduced the incidence of end-stage renal disease (ESRD) in comparison with a non angiotensin-converting enzyme inhibitor or non angiotensin II antagonist antihypertensive regimen.
CRD COMMENTARY -Selection of comparators
The authors justified the choice of the comparators, which represented a range of possible therapies for patients with DM-2 and nephropathy. You should decide whether they are valid comparators in your own setting. The authors stated that angiotensin-converting enzyme inhibitors and angiotensin II antagonists were not included because of the lack of reliable data from clinical trials.
Validity of estimate of measure of effectiveness
The effectiveness evidence was extracted from a published clinical trial, which was appropriate for the study question. The randomised design should have reduced the potential impact of selection bias, while double masking was appropriate to control for performance bias and assessment bias. The length of follow-up appears to have been appropriate. Most of the information on sample selection, patient follow-up and the use of power calculation was not
